Paolo Tombesi
2021 - Turning Point Therapeutics
Compensation breakdown
Bonus | $250,000 |
---|---|
Non-Equity Incentive Plan | $247,690 |
Option Awards | $2,609,323 |
Salary | $204,735 |
Stock Awards | $1,227,548 |
Other | $38,766 |
Total | $4,578,062 |
Tombesi received $2.6M in option awards, accounting for 57% of the total pay in 2021.
Tombesi also received $250K in bonus, $247.7K in non-equity incentive plan, $204.7K in salary, $1.2M in stock awards and $38.8K in other compensation.
Rankings
In 2021, Paolo Tombesi's compensation ranked 2,887th out of 12,415 executives tracked by ExecPay. In other words, Tombesi earned more than 76.7% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,887 | 77th |
Manufacturing | 1,149 | 79th |
Chemicals And Allied Products | 455 | 81st |
Drugs | 399 | 81st |
Pharmaceutical Preparations | 267 | 83rd |
Tombesi's colleagues
We found six more compensation records of executives who worked with Paolo Tombesi at Turning Point Therapeutics in 2021.
2021
Athena Countouriotis
Turning Point Therapeutics
Chief Executive Officer
2021
Mohammad Hirmand
Turning Point Therapeutics
Chief Medical Officer
2021
Annette North
Turning Point Therapeutics
General Counsel
2021
Siegfried PHD
Turning Point Therapeutics
Chief Scientific Officer
2021
Yi Larson
Turning Point Therapeutics
Chief Financial Officer
2021
Brian Baker
Turning Point Therapeutics
Former Senior Vice President, Finance and Administration
News
April 29, 2022
April 29, 2021
April 17, 2020
March 31, 2020
April 4, 2019